Experimental study to test the potential tumor promotion effect of a tooth bleaching agent.
Carbamide Peroxide is routinely employed as a whitener for tooth enamel. Oral mucosa protection is recommended to avoid inflammatory reactions. Experimental work has demonstrated its irritative effect on gastric mucosa when swallowed. The activity of certain oxidizing agents as tumoral promoters has been demonstrated and associated to their capacity to induce hyperplasia. Within this context it seemed of interest to assess the possible action of carbamide peroxide as a tumoral promoter in oral mucosa with or without a precancerous condition. Its action was tested in 2 models which are highly sensitive to chemical cancerization: a) Dorsum skin or SENCAR mice treated with carbamide peroxide daily or twice a week with or without prior initiation with dimethylbenz(a)anthracene (DMBA). Control mice were submitted to the standard carcinogenesis protocol, i.e. initiation with DMBA and promotion with 12-O-tetradecanoyl phorbol acetate (TPA). b) Hamster cheek pouch submitted to topical application of carbamide peroxide 3 times a week with or without prior initiation with DMBA, hamster cheek pouch submitted to repeated topical application of DMBA as a complete carcinogen: application twice a week in the control group and identical treatment + 1 weekly application of carbamide peroxide to evaluate its capacity to enhance the process. The effects were assessed between 1 and 14 weeks of treatment at different intervals for the different experimental protocols. The control cases exhibited hyperplasia and tumor induction in keeping with the known sequence for both carcinogenesis models. None of the cases revealed a promoter or enhancer capacity of carbamide peroxide. These results indicate the lack of risk involved in the application of carbamide peroxide even in oral mucosa with a precancerous condition due to the action of initiation agents such as tobacco and alcohol.
Collet
A M
AM
Department of Oral Pathology, Faculty of Dentistry, University of Buenos Aires. AMCOLLET@CAP.ODON.UBA.AR
Palmieri
M
M
Molinari
B
B
Schwint
A E
AE
Itoiz
M E
ME
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000009:adverse effects; D000818:Animals; D000077463:Carbamide Peroxide; D002273:Carcinogens / Q000009:adverse effects; D006224:Cricetinae; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D006965:Hyperplasia; D008297:Male; D008647:Mesocricetus; D051379:Mice; D018632:Mice, Inbred SENCAR; D009061:Mouth Mucosa / Q000187:drug effects; D009062:Mouth Neoplasms / Q000139:chemically induced; D016877:Oxidants / Q000009:adverse effects*; D010545:Peroxides / Q000009:adverse effects*; D011230:Precancerous Conditions / Q000139:chemically induced; D012878:Skin Neoplasms / Q000139:chemically induced; D013755:Tetradecanoylphorbol Acetate / Q000009:adverse effects; D014073:Tooth Bleaching / Q000009:adverse effects*; D014508:Urea / Q000009:adverse effects* / Q000031:analogs & derivatives*
D002273:Carcinogens; D004338:Drug Combinations; D016877:Oxidants; D010545:Peroxides; D000077463:Carbamide Peroxide; D015127:9,10-Dimethyl-1,2-benzanthracene; D014508:Urea; D013755:Tetradecanoylphorbol Acetate